NASDAQ:GTXI - GTX Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9401 0.00 (0.00 %) (As of 02/19/2019 09:52 AM ET)Previous Close$0.9440Today's Range$0.94 - $0.944952-Week Range$0.74 - $25.60Volume13,261 shsAverage Volume262,313 shsMarket Capitalization$22.61 millionP/E Ratio-0.54Dividend YieldN/ABeta2.54 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee. Receive GTXI News and Ratings via Email Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GTXI Previous Symbol CUSIP40052B10 Webwww.gtxinc.com Phone901-523-9700Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32Price-To-Earnings Trailing P/E Ratio-0.54 Forward P/E Ratio-0.57 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.53Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-30,430,000.00 Net MarginsN/A Return on Equity-126.41% Return on Assets-100.34%Miscellaneous Employees27 Outstanding Shares24,052,000Market Cap$22.61 million OptionableOptionable GTX (NASDAQ:GTXI) Frequently Asked Questions What is GTX's stock symbol? GTX trades on the NASDAQ under the ticker symbol "GTXI." How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) issued its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.09. View GTX's Earnings History. When is GTX's next earnings date? GTX is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for GTX. What price target have analysts set for GTXI? 2 brokerages have issued 12-month price objectives for GTX's stock. Their predictions range from $17.00 to $45.00. On average, they anticipate GTX's share price to reach $31.00 in the next year. This suggests a possible upside of 3,183.9% from the stock's current price. View Analyst Price Targets for GTX. What is the consensus analysts' recommendation for GTX? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX. Has GTX been receiving favorable news coverage? News headlines about GTXI stock have trended positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GTX earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of GTX's key competitors? Some companies that are related to GTX include Cumberland Pharmaceuticals (CPIX), Teligent (TLGT), Entasis Therapeutics (ETTX), Pharmaxis (PXSLY), Iterum Therapeutics (ITRM), Avadel Pharmaceuticals (AVDL), Alpine Immune Sciences (ALPN), Infinity Pharmaceuticals (INFI), Merrimack Pharmaceuticals (MACK), VERONA PHARMA P/S (VRNA), AVEO Pharmaceuticals (AVEO), Melinta Therapeutics (MLNT), Synergy Pharmaceuticals (SGYP), Provention Bio (PRVB) and Alimera Sciences (ALIM). Who are GTX's key executives? GTX's management team includes the folowing people: Dr. Robert James Wills Ph.D., Exec. Chairman (Age 65)Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)Dr. Diane C. Young, VP & Chief Medical Officer (Age 62) Who are GTX's major shareholders? GTX's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.93%), Geode Capital Management LLC (0.94%), Bank of America Corp DE (0.85%), Two Sigma Investments LP (0.55%), GSA Capital Partners LLP (0.45%) and Virtu Financial LLC (0.28%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX. Which institutional investors are selling GTX stock? GTXI stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and BlackRock Inc.. Company insiders that have sold GTX company stock in the last year include Diane C Young, Henry Patton Doggrell and Jason T Shackelford. View Insider Buying and Selling for GTX. Which institutional investors are buying GTX stock? GTXI stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE, GSA Capital Partners LLP, Virtu Financial LLC, Two Sigma Advisers LP and Two Sigma Investments LP. View Insider Buying and Selling for GTX. How do I buy shares of GTX? Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GTX's stock price today? One share of GTXI stock can currently be purchased for approximately $0.9440. How big of a company is GTX? GTX has a market capitalization of $22.71 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe. What is GTX's official website? The official website for GTX is http://www.gtxinc.com. How can I contact GTX? GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected] MarketBeat Community Rating for GTX (NASDAQ GTXI)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 213 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 387MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: Why is the Consumer Price Index (CPI) important?